Details for Patent: 7,304,078
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Which drugs does patent 7,304,078 protect, and when does it expire?
Patent 7,304,078 protects ZONTIVITY and is included in one NDA.
This patent has one hundred and sixty-four patent family members in thirty-seven countries.
Summary for Patent: 7,304,078
Title: | Thrombin receptor antagonists |
Abstract: | Heterocyclic-substituted tricyclics of the formula ##STR00001## or a pharmaceutically acceptable salt thereof, wherein: the dotted line represents an optional single bond; represents an optional double bond; n is 0 2; Q is cycloalkyl, optionally substituted by R.sup.13 and R.sup.14; R.sup.13 and R.sup.14 are independently selected from (C.sub.1 C.sub.6)alkyl, (C.sub.3 C.sub.8)cycloalkyl, --OH, (C.sub.1 C.sub.6)alkoxy, R.sup.27-aryl(C.sub.1 C.sub.6)alkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halogen and haloalkyl; or R.sup.13 and R.sup.14 together form a spirocyclic or a heterospirocyclic ring of 3 6 atoms; Het is a mono- or bi-cyclic optionally substituted heteroaryl group; and B is a bond, alkylene, or optionally substituted alkenylene or alkynylene, wherein the remaining substituents are as defined in the specification, are disclosed, as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, and cancer by administering said compounds. Combination therapy with other cardiovascular agents is also claimed. |
Inventor(s): | Chackalamannil; Samuel (Califon, NJ), Greenlee; William J. (Teaneck, NJ), Wang; Yuguang (North Brunswick, NJ), Wu; Wenxue (Princeton Junction, NJ), Veltri; Enrico P. (Princeton, NJ), Xia; Yan (Edison, NJ) |
Assignee: | Schering Corporation (Kenilworth, NJ) |
Application Number: | 10/412,982 |
Patent Claim Types: see list of patent claims | Compound; Composition; Use; |
Drugs Protected by US Patent 7,304,078
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Xspire Pharma | ZONTIVITY | vorapaxar sulfate | TABLET;ORAL | 204886-001 | May 8, 2014 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | Y | REDUCTION OF THROMBOTIC CARDIOVASCULAR EVENTS | See Plans and Pricing | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 7,304,078
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Argentina | 028952 | See Plans and Pricing | |||
Argentina | 039570 | See Plans and Pricing | |||
Argentina | 045809 | See Plans and Pricing | |||
Argentina | 047088 | See Plans and Pricing | |||
Argentina | 098260 | See Plans and Pricing | |||
Austria | 368659 | See Plans and Pricing | |||
Austria | 378330 | See Plans and Pricing | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |